A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC) (MOUNTAINEER) - Strickler, J; Niedzwiecki, D; Zemla, T (J Clin Oncol, 2017)